Integra LifeSciences
IART
278 hedge funds and large institutions have $4.71B invested in Integra LifeSciences in 2022 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 112 increasing their positions, 92 reducing their positions, and 24 closing their positions.
28% more call options, than puts
Call options by funds: $10.2M | Put options by funds: $7.96M
22% more repeat investments, than reductions
Existing positions increased: 112 | Existing positions reduced: 92
21% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 24
0% more funds holding
Funds holding: 277 → 278 (+1)
1.7% less ownership
Funds ownership: 91.4% → 89.7% (-1.7%)
9% less capital invested
Capital invested by funds: $5.16B → $4.71B (-$449M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$18.6M |
| 2 |
Millennium Management
New York
|
+$15.2M |
| 3 |
D.E. Shaw & Co
New York
|
+$15M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$11.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$10.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$153M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$92.3M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$30.6M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$18.2M |
| 5 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
-$17.3M |
IART Hedge Fund Activity: Q1 2022 in Review
278 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q1 2022, worth a combined $4.71B — down 8.7% from $5.16B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new IART positions and 24 closed out — a net gain of 5 holders — while 112 added to existing stakes and 92 trimmed.
The largest buyer was Two Sigma Investments, opening a new position worth an estimated $18.6M. The largest seller was Wellington Management Group, cutting an estimated $153M.
- 278 institutional investors held Integra LifeSciences (IART) as of Q1 2022, up from 277 in Q4 2021.
- Funds reported $4.71B of Integra LifeSciences stock for Q1 2022, down 8.7% quarter-over-quarter.
- 29 funds opened new Integra LifeSciences positions in Q1 2022 and 24 closed out, a net change of +5 holders.
- The largest Integra LifeSciences buyer in Q1 2022 was Two Sigma Investments, an estimated $18.6M added.
- The largest Integra LifeSciences seller in Q1 2022 was Wellington Management Group, an estimated $153M sold.
Based on aggregated 13F filings for Q1 2022.